Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
about
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.A phase 2 study of vorinostat in acute myeloid leukemiaEZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsCurrent Management Strategies in Breast Cancer by Targeting Key Altered Molecular PlayersDengue Virus Induces Novel Changes in Gene Expression of Human Umbilical Vein Endothelial CellsThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyFurther evidence to support the melanocytic origin of MDA-MB-435Tandem ChoRE and CCAAT motifs and associated factors regulate Txnip expression in response to glucose or adenosine-containing moleculesExpression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the BreastEpigenetics as a therapeutic target in breast cancer.Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.A Multifaceted Role for Myd88-Dependent Signaling in Progression of Murine Mammary Carcinoma.A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocketDeacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research G
P2860
Q24535620-810DA5BB-373C-4512-AAF0-336B0B6B1D94Q24643266-FF24A49A-180B-4F7E-92CA-037614899CE5Q24672969-82B560AD-F304-497A-AE23-81B4ACF6AA0BQ26765877-6A9A40C2-7820-4CEF-A469-1F409102BF33Q27485730-C07D0718-A6BB-4B90-9085-DA5C2FF926FBQ28076473-82CED929-41DA-4681-B8B5-39024B87E240Q30857872-2C3D64B3-DFA7-497F-9CDE-EA4ABF911ABEQ33520238-355B2741-816A-428D-924A-7B3D4A4067EEQ34779627-B20E3A5E-E79F-4E1A-A11A-A650AD37A03CQ36449057-42C5C39B-2653-446E-A76B-24B9E4589DB6Q36996317-7018696E-06A5-48EC-91C6-C6DD0389C079Q37031561-31008F1C-0B0C-454C-BB55-FF24A7FBF96FQ37375375-273680F8-44D6-4402-BD76-9480CAAAF5D8Q37512730-66351DC7-EA6E-4ADA-822A-87207D673D35Q37531368-66284BD9-D0D8-4D1C-ACB6-887CD44D682DQ37684405-22D93656-8E6F-49AA-AADA-6BF88216A056Q38204487-E133A0D6-3F38-4B04-A37A-03A453AC20F8Q39635485-712D7469-C7C1-4786-86C9-E3FF0A85B881Q39742002-49A2E53D-BD29-4B28-BBC9-124039EF766BQ40396320-26E5AC3D-84C4-41E4-808C-E30DA6ED47EDQ40952382-D34DF99B-608D-4022-8C21-E7622736929EQ41593165-D8F83E28-E782-4FCD-A064-0B33BD4A9066Q46251027-8E01CFB4-699C-40A7-9DE8-2EA0D47C1B48Q46557812-79F5AF62-3055-47BF-856F-D675839265EFQ48758277-9B654C8E-747F-4257-A615-4C26A3002B4B
P2860
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@ast
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@en
type
label
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@ast
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@en
prefLabel
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@ast
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@en
P1433
P1476
Suberoylanilide hydroxamic aci ...... human breast cancer treatment
@en
P2093
P304
P407
P577
2000-10-01T00:00:00Z